Results 11 to 20 of about 1,936 (153)

Failure of ceftolozane‐tazobactam salvage therapy in complicated pneumonia with lung abscess

open access: yesClinical Case Reports, 2018
Key Clinical Message Treatment of Pseudomonas aeruginosa remains challenging, despite the availability ceftolozane‐tazobactam. We report a treatment failure with ceftolozane‐tazobactam salvage therapy for pneumonia complicated by lung abscess.
Paul O. Lewis   +4 more
doaj   +2 more sources

Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis [PDF]

open access: yesMicrobiology Spectrum, 2023
Ceftolozane/tazobactam is approved for the treatment of patients from birth to
Emmanuel Roilides   +7 more
doaj   +2 more sources

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa [PDF]

open access: yesmBio, 2018
Pseudomonas aeruginosa produces a class C β-lactamase (e.g., PDC-3) that robustly hydrolyzes early generation cephalosporins often at the diffusion limit; therefore, bacteria possessing these β-lactamases are resistant to many β-lactam antibiotics.
Melissa D. Barnes   +11 more
doaj   +2 more sources

Treatment of Polymicrobial Osteomyelitis with Ceftolozane-Tazobactam: Case Report and Sensitivity Testing of Isolates [PDF]

open access: yesCase Reports in Infectious Diseases, 2016
Stenotrophomonas maltophilia is an inherently multidrug resistant (MDR) opportunistic pathogen with many mechanisms of resistance. SENTRY studies reveal decreasing sensitivities of S.
Jeffrey C. Jolliff   +4 more
doaj   +2 more sources

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps

open access: yesCurrent Therapeutic Research, 2017
Background: Elastomeric pumps are often used to administer intravenous antibiotics in the outpatient setting, but effective infusion requires that the drug remain stable in solution throughout the procedure. Objective: To determine the chemical stability
Joseph Terracciano, PhD   +2 more
doaj   +2 more sources

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015)

open access: yesBrazilian Journal of Infectious Diseases, 2017
This study evaluated the in vitro activity of ceftolozane-tazobactam and comparator agents tested against Latin American isolates of Enterobacteriaceae and Pseudomonas aeruginosa from patients with health care-associated infections.
Michael A. Pfaller   +5 more
doaj   +2 more sources

Antibiotic Susceptibility of Aerobic and Facultative Anaerobic Gram-Negative Rods in Hong Kong and Implications on Usefulness of Ceftazidime-Avibactam and Ceftolozane-Tazobactam

open access: yesAntibiotics
Due to the increasing resistance of aerobic and facultative anaerobic Gram-negative rods, ceftazidime-avibactam and ceftolozane-tazobactam have been launched in the market in the last few years.
Jade L. L. Teng   +9 more
doaj   +2 more sources

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections

open access: yesTherapeutics and Clinical Risk Management, 2016
Stephanie E Giancola,1 Monica V Mahoney,2 Tiffany E Bias,3,4 Elizabeth B Hirsch2,51Department of Pharmacy, St Mary’s Medical Center, Huntington, WV, 2Beth Israel Deaconess Medical Center, Boston, MA, 3Hahnemann University Hospital, 4Drexel ...
Giancola SE   +3 more
doaj   +1 more source

Safety and efficacy of ceftolozane/tazobactam plus metronidazole versus meropenem from a phase 2, randomized clinical trial in pediatric participants with complicated intra-abdominal infection [PDF]

open access: yes, 2023
BACKGROUND: Ceftolozane/tazobactam, a cephalosporin-β-lactamase inhibitor combination, is approved for the treatment of complicated urinary tract infections and complicated intra-abdominal infections (cIAI).
Popejoy, Myra W   +23 more
core   +1 more source

Evaluation of in vitro activity of ceftolozane–tazobactam against recent clinical bacterial isolates from Brazil – the EM200 study

open access: yesBrazilian Journal of Infectious Diseases, 2020
Background: The emergence of antibiotic resistance is increasing and there are few effective antibiotics to treat infections caused by resistant and multidrug resistant bacterial pathogens.
Felipe Francisco Tuon   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy